MOTEGRITY
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $2,438 | 4 | 2 |
| 2022 | $35,240 | 1,327 | 1,194 |
| 2021 | $443,896 | 11,584 | 5,024 |
| 2020 | $390,788 | 7,404 | 4,048 |
| 2019 | $21,567 | 35 | 27 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $345,132 | 20,065 | 38.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $343,101 | 150 | 38.4% |
| Consulting Fee | $95,124 | 37 | 10.6% |
| Grant | $50,000 | 1 | 5.6% |
| Unspecified | $40,500 | 9 | 4.5% |
| Travel and Lodging | $20,050 | 89 | 2.2% |
| Education | $22.36 | 3 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC SUBJECTS AGED 6 MONTHS TO 17 YEARS WITH FUNCTIONAL CONSTIPATION, CONSISTING OF A 12-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED PART (PART A) TO EVALUATE EFFICACY AND SAFETY FOLLOWED BY A 36-WEEK DOUBLE-BLIND EXTENSION PART (PART B) TO DOCUMENT LONG-TERM SAFETY UP TO WEEK 48 | Takeda Pharmaceuticals U.S.A., Inc. | $40,500 | 0 |
Top Doctors Receiving Payments for MOTEGRITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $90,636 | 13 |
| , MD | Gastroenterology | Houston, TX | $49,254 | 30 |
| , MD | Gastroenterology | Robbinsdale, MN | $26,072 | 32 |
| , DO | Gastroenterology | Columbus, OH | $23,618 | 32 |
| , M.D., PH.D | Gastroenterology | Jackson, MS | $22,852 | 21 |
| , M.D | Gastroenterology | Chicago, IL | $22,497 | 14 |
| , M.D | Gastroenterology | Gurnee, IL | $21,514 | 24 |
| , M.D | Gastroenterology | Newark, NJ | $20,651 | 35 |
| , M.D | Gastroenterology | West Hollywood, CA | $18,711 | 31 |
| , M.D | Internal Medicine | San Francisco, CA | $16,399 | 11 |
| , MD | Gastroenterology | Greensboro, NC | $14,763 | 11 |
| , D.O | Gastroenterology | Farmington Hills, MI | $13,754 | 21 |
| , M.D | Gastroenterology | Philadelphia, PA | $13,150 | 14 |
| , M.D | Gastroenterology | Cranston, RI | $10,930 | 13 |
| , MD | Internal Medicine | New Haven, CT | $10,673 | 7 |
| , M.D | Gastroenterology | Sacramento, CA | $10,318 | 4 |
| , M.D | Gastroenterology | Charlotte, NC | $10,133 | 11 |
| , MD | Gastroenterology | New York, NY | $9,121 | 15 |
| , M.D | Gastroenterology | Delray Beach, FL | $8,767 | 17 |
| , M.D | Gastroenterology | Olathe, KS | $8,546 | 6 |
| , MD | Gastroenterology | Merrick, NY | $7,991 | 22 |
| Chaudry Ahmad Cheema | — | Rock Island, IL | $7,588 | 6 |
| , MD | Gastroenterology | Brooklyn, NY | $7,472 | 23 |
| , M.D | Internal Medicine | La Jolla, CA | $7,159 | 6 |
| , PH.D; M.D | Gastroenterology | Lebanon, NH | $6,525 | 1 |
Manufacturing Companies
- Takeda Pharmaceuticals U.S.A., Inc. $882,205
- Shire North American Group Inc $11,724
Product Information
- Type Drug
- Total Payments $893,929
- Total Doctors 7,887
- Transactions 20,354
About MOTEGRITY
MOTEGRITY is a drug associated with $893,929 in payments to 7,887 healthcare providers, recorded across 20,354 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2019 to 2023. In 2023, $2,438 was paid across 4 transactions to 2 doctors.
The most common payment nature for MOTEGRITY is "Food and Beverage" ($345,132, 38.6% of total).
MOTEGRITY is associated with 1 research study, including "PHASE 3, MULTICENTER, RANDOMIZED STUDY WITH 2 DIFFERENT DOSES OF PRUCALOPRIDE ADMINISTERED TO MALE AND FEMALE PEDIATRIC SUBJECTS AGED 6 MONTHS TO 17 YEARS WITH FUNCTIONAL CONSTIPATION, CONSISTING OF A 12-WEEK DOUBLE-BLIND, PLACEBO-CONTROLLED PART (PART A) TO EVALUATE EFFICACY AND SAFETY FOLLOWED BY A 36-WEEK DOUBLE-BLIND EXTENSION PART (PART B) TO DOCUMENT LONG-TERM SAFETY UP TO WEEK 48" ($40,500).